Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
MLTX MoonLake Immunotherapeutics	$40.18 +4.4%	$38.43	$31.42 ▼ $58.26	$2.57B	1.31	354,085 shs	345,524 shs
RCUS Arcus Biosciences	$8.82 +6.5%	$8.38	$6.50 ▼ $18.98	$933.38M	0.88	832,636 shs	2.67 million shs
SMMT Summit Therapeutics	$25.26 +5.4%	$22.06	$2.10 ▼ $36.91	$18.76B	-0.94	3.85 million shs	3.03 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+0.91%
MLTX MoonLake Immunotherapeutics	+4.45%	-4.11%	+15.13%	-7.06%	-1.81%
RCUS Arcus Biosciences	+6.46%	-1.27%	+9.03%	-26.48%	-47.25%
SMMT Summit Therapeutics	+5.43%	-9.85%	+8.69%	+32.39%	+443.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	1.9177 of 5 stars	3.5	0.0	0.0	0.0	3.7	2.5	0.0
RCUS Arcus Biosciences	2.733 of 5 stars	4.5	1.0	0.0	0.0	1.1	4.2	0.0
SMMT Summit Therapeutics	2.909 of 5 stars	4.5	1.0	0.0	0.0	4.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	3.00	Buy	$80.50	100.35% Upside
RCUS Arcus Biosciences	2.91	Moderate Buy	$25.67	191.17% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	48.06% Upside

Current Analyst Ratings Breakdown

Latest DCPH, MLTX, SMMT, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/30/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
RCUS Arcus Biosciences	$141M	6.62	N/A	N/A	$6.17 per share	1.43
SMMT Summit Therapeutics	$700K	26,799.63	N/A	N/A	$0.11 per share	229.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
MLTX MoonLake Immunotherapeutics	-$36.01M	-$1.89	N/A	N/A	N/A	N/A	-15.54%	-15.09%	5/13/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	N/A

Latest DCPH, MLTX, SMMT, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
2/26/2025	Q4 2024	MLTX MoonLake Immunotherapeutics	-$0.63	-$0.72	-$0.09	-$0.72	N/A	N/A
2/25/2025	Q4 2024	RCUS Arcus Biosciences	-$1.17	-$1.03	+$0.14	-$1.03	$29.38 million	$36.00 million
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
RCUS Arcus Biosciences	0.08	5.24	5.24
SMMT Summit Therapeutics	N/A	8.31	8.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCPH Deciphera Pharmaceuticals	70.96%
MLTX MoonLake Immunotherapeutics	93.85%
RCUS Arcus Biosciences	92.89%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
DCPH Deciphera Pharmaceuticals	4.67%
MLTX MoonLake Immunotherapeutics	12.02%
RCUS Arcus Biosciences	12.30%
SMMT Summit Therapeutics	88.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable

DCPH, MLTX, SMMT, and RCUS Headlines

Recent News About These Companies

Hsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 13 at 3:30 AM | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Average Target Price from Brokerages

May 13 at 1:45 AM | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Raised to "Strong-Buy" at TD Cowen

May 12 at 7:55 AM | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Buy" from Analysts

May 12 at 4:46 AM | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Balyasny Asset Management L.P.

May 12 at 4:34 AM | marketbeat.com

Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain

May 9, 2025 | insidermonkey.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Bosun Asset Management LLC

May 9, 2025 | marketbeat.com

The Manufacturers Life Insurance Company Purchases 181,185 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)

May 8, 2025 | marketbeat.com

Can Summit Therapeutics Stock Double Your Money?

May 7, 2025 | finance.yahoo.com

Bayesian Capital Management LP Invests $1.20 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 7, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Sell" at StockNews.com

May 7, 2025 | americanbankingnews.com

Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know

May 6, 2025 | zacks.com

Bellevue Group AG Has $3.04 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 6, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Issues Quarterly Earnings Results

May 5, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results

May 5, 2025 | marketbeat.com

Tower Research Capital LLC TRC Raises Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 5, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Price Target Raised to $41.00

May 5, 2025 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading 16.9% Higher After Better-Than-Expected Earnings

May 4, 2025 | marketbeat.com

Why Summit Therapeutics Inc. (SMMT) Soared Last Week

May 4, 2025 | insidermonkey.com

250,000 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by Boxer Capital Management LLC

May 4, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Makes New $1.20 Million Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCPH, MLTX, SMMT, and RCUS Company Descriptions

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$40.18 +1.71 (+4.45%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$41.85 +1.67 (+4.16%)

As of 04:40 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Arcus Biosciences NYSE:RCUS

$8.82 +0.54 (+6.46%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$8.78 -0.03 (-0.34%)

As of 04:12 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Summit Therapeutics NASDAQ:SMMT

$25.26 +1.30 (+5.43%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$24.82 -0.44 (-1.74%)

As of 04:07 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time